Ipsen Opts-in to Join Exelixis With Ongoing Development of Cabometyx for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results
Ipsen Opts-in to Join Exelixis With Ongoing Development of Cabometyx for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results 1 Detailed results will be presented at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Participation in the collaboration will provide Ipsen with access to full trial data to support potential future regulatory submissions Disclaimer: Intended for international media and investor audiences only Regulatory News: Ip...
Source: finanznachrichten.de